Анализ влияния профилактики реакции трансплантат против хозяина на аллореактивность естественных киллерных клеток донора после аллогенной трансплантации гемопоэтических стволовых клеток с деплецией /TCR/CD19+ лимфоцитов у детей с острыми лейкозами
Автор: Захарова В.В., Шеховцова Ж.Б., Шрагина О.А., Райкина Е.В., Илюшина М.А., Музалевский Я.О., Кочетов А.Г., Шелихова Л.Н., Масчан М.А.
Журнал: Вестник медицинского института "РЕАВИЗ": реабилитация, врач и здоровье @vestnik-reaviz
Рубрика: Клиническая медицина
Статья в выпуске: 1 (37), 2019 года.
Бесплатный доступ
Одной из первых популяций лимфоцитов, восстанавливающейся после аллогенной трансплантации гемопоэтических стволовых клеток (ГСК) является популяция естественных киллерных клеток (NK клетки). Молекулы человеческого лейкоцитарного антигена ( Human Leukocyte Antigen, HLA ) служат лигандами для семейства KIR ( killer cell immunoglobulinlike-receptors, KIRs ) рецепторов NK клеток, а NK -аллореактивность, в свою очередь, основывается как на KIR - HLA несоответствии между донором и реципиентом, так и на KIR генотипе донора. Выводы большого количества современных исследований указывают на зависимость эффективности развития реакции трансплантат-против-лейкоза от множества факторов, среди которых KIR генотип донора и проведение профилактики реакции трансплантат-против-хозяина (РТПХ). Целью данного исследования являлось изучение влияния KIR генотипа NK клеток доноров на риск развития рецидива и выживаемость в выборке пациентов с острыми лейкозами и с одинаковым видом профилактики РТПХ после проведения им HLA -гаплоидентичной родственной и HLA -идентичной неродственной аллогенной трансплантации ГСК...
Иммуноглобулинподобные рецепторы киллерных клеток, kir типирование, hla типирование, трансплантация гемопоэтических стволовых клеток
Короткий адрес: https://sciup.org/143168483
IDR: 143168483 | УДК: 616.155
The influence of graft-versus-host disease prophylaxis on the donor natural killer cell alloreactivity after /TCR/CD19+-depleted allogeneic hematopoietic stem cell transplantation in pediatric patients with acute leukemia
Natural killer (NK) cells form the first lymphocyte population recovering after an allogeneic hematopoietic stem cell transplantation (HSCT). Human Leukocyte Antigen (HLA) molecules serve as ligands for KIR (killer cell immunoglobulinlike-receptors, KIRs) family receptors and NK-alloreactivity is based on a KIR-HLA mismatch between donor and patient as well as the donor’s KIR genotype. A large number of studies points out that the effectiveness of the graft-versus-leukemia reaction depends on many factors, specifically, donor’s KIR genotype and graft-versus-host disease (GVHD) prophylaxis regimen. Aim: The aim of this study was the evaluating of donor’s KIR genotype influence on the relapse risk and survival in acute leukemia patients with an identical GVHD prophylaxis regimen after allogeneic HLA-haploidentical related and HLA-identical unrelated HSCT. Matherials and methods: The study includes 47 patients (the median age 9) with acute myeloid leukemia (AML) (n = 34) and acute lymphoid leukemia (ALL) (n = 13) received first HLA-identical unrelated (n = 20) and HLA-haploidentical (n = 27) with α/βTCR-depleted allogeneic HSCT...
Список литературы Анализ влияния профилактики реакции трансплантат против хозяина на аллореактивность естественных киллерных клеток донора после аллогенной трансплантации гемопоэтических стволовых клеток с деплецией /TCR/CD19+ лимфоцитов у детей с острыми лейкозами
- Caligiuri M. Human Natural killer cells. Blood. 2008; 112: 461-469.
- Vivier E. et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011; 331:44-49
- Colucci F. et al. What does it take to make a natural killer? Nature Reviews Immunology. 2003; 3:413-425.
- Lee S. et al. Keeping NK cells in highly regulated antiviral warfare. Trends in Immunology. 2007; 28:252-259.
- Smyth M. et al. New aspects of natural-killer-cell surveillance and therapy of cancer. Nature Reviews Cancer; 2:850-861
- Cooper M. et.al. Human Natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. 2001. Blood; 97:3146-3151.
- Freud A. et al. Human Natural killer cell development. Nature Reviews Immunology. 2006; 214:56-72.
- Jacobs R. et al. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. European Journal of Immunology. 2001; 31:3121-3127.
- Fehniger T. et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 2003; 101:3052-3057.
- Cooper M. et al. NK cell and DC interactions. Trends in Immunology. 2004; 25:47-52.
- Lanier L. et al. Natural killer cell receptor signaling. Current opinion in Immunology. 2003; 15:308-314.
- McQueen K.L., Parham P. Variable receptors controlling activation and inhibition of NK cells. Current opinion in Immunology. 2002;14:615-21.
- Long E. et al. Inhibition of natural killer cell activation signals by killer cell immunoglobulin-like receptors (CD158). Nature Reviews Immunology. 2001; 181:223-233.
- Ljunggren H.G., Karre K. In search of the «missing self»: MHC molecules and NK cell recognition. Immunology today. 1990;11:237-44.
- Rugerri L., Capanni M., Casucci M., Volpi I., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333-39
- Uhrberg M., Valiante NM., Shum BP., et al. Human diversity in killer cell inhibitory receptor genes. Immunity. 1997;7:753-63.
- Witt C.S., Dewing C.B., Sayer D.C., et al. Population frequencies and putative haplotypes of the killer cell immunoglobulin-like receptor sequences and evidence for recombination. Transplantation. 1999;68:1784-89.
- Mehra N.K., Kaur G., McCluskey J., et al. The HLA complex in Biology and Medicine: A Resource Book. 2010; 31: 526-27.
- Savani B.N., Mielke S., Adams S., Uribe M. et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid Leukemias but not with acute lymphoblastic Leukemia. Leukemia. 2007;21:2145-52
- Maschan M., Shelikhova L., Ilushina M. et al. TCR-alpha/beta and CD19 depletion and threosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia. Bone Marrow Transplant 2016;51(5):668-74
- Balashov D., Shcherbina A., Maschan M. et al. Single-center experience of unrelated and haploidentical stem cell transplantation with TCR-alpha/beta and CD19 depletion in children with primary immunodeficiency syndromes. Biol Blood Marrow Transplant. 2015;21(11):1955-62
- Laberko A., Bogoyavlenskaya A., Shelikhova L. et al. Risk Factors and the Clinical impact of Cytomegalovirus and Epstein-Barr Virus infections in Pediatric Recipients of TCR-alpha/betaand CD19-Depleted Grafts. Biol Blood Marrow Transplant. 2017;23(3):483-490.
- Balashov D., Laberko A., Shcherbina A. et al. A Conditioning Regimen with Plerixafor is Safe and Improves the Outcome of TCR-alpha/beta and CD19+-Cell-Depleted Stem Cell Transplantation in Patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018.
- http://hla.alleles.org/dictionary/index.html
- Biassoni R., Vanni I., Ugolotti E. Killer Immunoglobulin-like Receptors and Their Ligands. Histocompatibility book. 2012. 6: 97-99.
- http://www.ebi.ac.uk/ipd/kir
- Cooley S., Weisdorf DJ., Guethlein LA. et al. Donor selection for natural killer receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116:2411-19.
- Oevermann L., Sebastian U. Michaelis, Markus Mezger, Peter Lang, et al. KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL. Blood. 2014; 124:2744-47.
- Shilling H.G., McQueen K.L., Cheng N.W. et al. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic stem cell transplantation. Blood. 2003; 101:3730-40.
- Pende D., Marcenaro S., Falco M., et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: Evaluation of the functional role of activating KIR and re-definition of inhibitory KIR specificity. Blood. 2008; 113:3119-29.
- Rugerri L., Mancusi A., Capanni M. et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia: Challenging its predictive value. Blood. 2007; 110:433-40.
- Locatelli F., Pende D., Maccario R. et al. Haploidentical hematopoietic stem cell transplantation for the treatment of high-risk leukemias: How NK cells make the difference. Clin Immunol. 2009; 133(2):171-8.
- Triplett B., Handgretinger R., Pui C.H., et al. KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia. Blood. 2006; 107:1238-39.
